Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.

ABSTRACT:

Background

Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL).

Methods

Thirteen patients were treated with escalating doses of CD19-directed CARTs between 1 × 10⁶ and 50 × 10⁶ CARTs/m². Leukapheresis, manufacturing and administration of CARTs were performed in-house.

Results

For all patients, CART manufacturing was feasible. None of the patients developed any grade of Immune effector cell-associated neurotoxicity syndrome (ICANS) or a higher-

SUBMITTER: Schubert ML 

PROVIDER: S-EPMC10363324 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature